The combination of vibostolimab and pembrolizumab showed promising anti-tumor efficacy and manageable toxicity in patients with advanced solid tumors and anti-PD-1/PD-L1-naive NSCLC [18]. This evidence concerns the gene PDCD1 and neoplasm.